Shire SHP
This security is delisted
Dividend Summary
The previous Shire dividend was 41.6c and it went ex over 3 years ago and it was paid over 3 years ago.
There are typically 2 dividends per year (excluding specials), and the dividend cover is approximately 13.8.
Latest Dividends
| Summary | Previous dividend | Next dividend |
|---|---|---|
| Status | Forecast | – |
| Type | Final | – |
| Per share | 29.873p (41.6c) | – |
| Declaration date | – | – |
| Ex-div date | 04 Mar 2021 (Thu) | – |
| Pay date | 21 Apr 2021 (Wed) | – |
Enter the number of Shire shares you hold and we'll calculate your dividend payments:
Previous Payment
£29.87 ($41.60)
Paid on 21 Apr 2021 (Wed)
Next Payment
–
Free Email Notification
Sign up for Shire and we'll email you the dividend information when they declare.
Add Shire to receive free notifications when they declare their dividends.
Your account is set up to receive Shire notifications.
The table below shows the full dividend history for Shire
| Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
|---|---|---|---|---|---|---|---|---|
| Forecast | Final | – | 04 Mar 2021 | 21 Apr 2021 | USD | Sign up | — | |
| Forecast | Interim | – | 03 Sep 2020 | 16 Oct 2020 | USD | Sign up | — | |
| Forecast | Final | – | 05 Mar 2020 | 22 Apr 2020 | USD | Sign up | — | |
| Forecast | Interim | – | 05 Sep 2019 | 18 Oct 2019 | USD | Sign up | — | |
| Forecast | Final | – | 07 Mar 2019 | 23 Apr 2019 | USD | Sign up | — | |
| Paid | Interim | – | 06 Sep 2018 | 19 Oct 2018 | USD | 4.1p | 5.6c | 😞 |
| Paid | Final | – | 08 Mar 2018 | 24 Apr 2018 | USD | 23p | 29.79c | 😒 |
| Paid | Interim | 03 Aug 2017 | 07 Sep 2017 | 20 Oct 2017 | USD | 3.8p | 5.09c | 😒 |
| Paid | Final | 16 Feb 2017 | 09 Mar 2017 | 25 Apr 2017 | USD | — | 25.7c | |
| Paid | Interim | 02 Aug 2016 | 08 Sep 2016 | 07 Oct 2016 | USD | 3.1p | 4.63c | 😞 |
| Paid | Final | – | 10 Mar 2016 | 12 Apr 2016 | USD | — | 22.16c | |
| Paid | Interim | 23 Jul 2015 | 03 Sep 2015 | 02 Oct 2015 | USD | — | 4.21c | |
| Paid | Final | 12 Feb 2015 | 12 Mar 2015 | 14 Apr 2015 | USD | — | 19.09c | |
| Paid | Interim | 01 May 2014 | 03 Sep 2014 | 03 Oct 2014 | USD | — | 3.83c | |
| Paid | Final | 24 Oct 2013 | 05 Mar 2014 | 08 Apr 2014 | USD | — | 16.93c | |
| Paid | Interim | 25 Jul 2013 | 04 Sep 2013 | 03 Oct 2013 | USD | — | 3c | |
| Paid | Final | 14 Feb 2013 | 06 Mar 2013 | 09 Apr 2013 | USD | — | 14.6c | |
| Paid | Interim | – | 05 Sep 2012 | 04 Oct 2012 | USD | — | 2.73c | |
| Paid | Final | – | 07 Mar 2012 | 12 Apr 2012 | GBP | — | 7.96p | |
| Paid | Interim | – | 07 Sep 2011 | 06 Oct 2011 | GBP | — | 1.52p | |
| Paid | Final | – | 09 Mar 2011 | 07 Apr 2011 | GBP | — | 6.73p | |
| Paid | Interim | – | 08 Sep 2010 | 07 Oct 2010 | GBP | — | 1.41p | |
| Paid | Final | – | 31 Dec 2009 | 31 Dec 2009 | GBP | — | 7.21p | |
| Paid | Final | – | 31 Dec 2008 | 31 Dec 2008 | GBP | — | 6.55p | |
| Paid | Final | – | 31 Dec 2007 | 31 Dec 2007 | GBP | — | 4.36p | |
| Paid | Final | – | 31 Dec 2006 | 31 Dec 2006 | GBP | — | 3.74p |
| Year | Amount | Change |
|---|---|---|
| 2006 | 3.74p | — |
| 2007 | 4.36p | 16.6% |
| 2008 | 6.55p | 50.2% |
| 2009 | 7.21p | 10.1% |
| 2010 | 8.14p | 12.9% |
| 2011 | 9.48p | 16.5% |
| 2012 | 11.13p | 17.4% |
| 2013 | 12.12p | 8.9% |
| 2014 | 14.65p | 20.9% |
| 2015 | 18.01p | 22.9% |
| 2016 | 24.16p | 34.1% |
| 2017 | 25.196513p | 4.3% |
| 2018 | 30.382494p | 20.6% |
| 2019 | 35.529893p | 16.9% |
| 2020 | 35.109019p | -1.2% |
Shire Optimized Dividend Chart
The chart below shows the optimized dividends for this security over a rolling 12-month period.
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on
- 52 Week Low
- 0.0% on
- Next Ex-Div-Date Countdown
- Sign Up Required
About Shire
Shire is a leading UK pharmaceutical company. It's products include products include include Vyvanse, Adderall, XR, Intuniv, Lialda, Pentasa, Fosrenol, Replagal, Elaprase, Vpriv, Firazyr and Dermagraft.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- United Kingdom
- Share Price
- £45.06 (closing price on 04 Nov 2020)
- Shares in Issue
- 562 million
- Market Cap
- £25.3bn
- 13.8
- 10+
- Market Indices
- FTSE 350, FTSE 100, CBOE 350, CBOE 100
- Investor Relations URL
- Sign Up Required
- Financial Calendar URL
- Sign Up Required
- Dividend History URL
- Sign Up Required
- Home Page URL
- https://www.shire.com
Shire increases its 2014 final dividend by 12.7% in $ terms
DIVIDEND
In respect of the six months ended December 31, 2014 the Board has resolved to
pay an interim dividend of 19.09 US cents per Ordinary Share (2013: 16.93 US
cents per Ordinary Share).
Dividend payments will be made in Pounds Sterling to holders of Ordinary
Shares and in US Dollars to holders of ADSs. A dividend of 12.51(1) pence per
Ordinary Share (2013: 10.21 pence) and 57.27 US cents per ADS (2013: 50.79 US
cents) will be paid on April 14, 2015 to shareholders on the register as at
the close of business on March 13, 2015.
Together with the first interim payment of 3.83 US cents per Ordinary Share
(2013: 3.00 US cents per Ordinary Share), this represents total dividends for
2014 of 22.92 US cents per Ordinary Share (2013: 19.93 US cents per Ordinary
Share), an increase of 15% in US Dollar terms.
Shire increases 2013 Interim dividend by 12%
EXECUTING OUR STRATEGY- Further enhanced organic growth and improved operating margins- Progression of our late stage pipeline addressing unmet needs including:- Lifitegrast for dry eye disease and LDX for binge eating and major depressive disorders- Continued but focused R&D investment in other development opportunities- Focus on growth and value-driving business development- Good progress integrating three divisions into a simplified `One Shire'organization to create operating leverage, drive fast decisions and focus on growth-driving productsFlemming Ornskov, M.D., Chief Executive Officer, commented:"We are pleased with our Q2 results, have made good progress and have returned to higher growth.We're successfully executing our strategy, which is to grow by focusing on innovation-driven specialty products through both R&D and M&A. We've sharpened our focus on commercial excellence and we're enhancing our pipeline productivity. Our late Phase 3 projects lifitegrast and LDX for BED are progressing well and are programs in which we have increasing confidence.Our strategy has been designed to deliver further enhanced growth. We anticipate delivering full year double digit Non GAAP earnings growth in 2013 and are confident in our ability to grow operating margins going forward."
Shire Increases 2012 final dividend by 18%
Financial Highlights Full Year 2012Product sales $4,407 million +12%Product sales excluding ADDERALL XR $3,978 million +16%Total revenues $4,681 million +10%Non GAAP operating income $1,474 million +9%US GAAP operating income $949 million -14%Non GAAP diluted earnings per ADS $6.10 +14%US GAAP diluted earnings per ADS $3.93 -13%Non GAAP cash generation $1,637 million +18%Non GAAP free cash flow $1,256 million +43%US GAAP net cash provided by operating activities $1,383 million +29%DIVIDENDIn respect of the six months ended December 31, 2012 the Board has resolved topay an interim dividend of 14.60 US cents per ordinary share (2011: 12.59 UScents per ordinary share).Dividend payments will be made in Pounds Sterling to ordinary shareholders andin US Dollars to holders of ADSs. A dividend of 9.39 pence per ordinary share(2011: 7.96 pence) and 43.80 US cents per ADS (2011: 37.77 US cents) will bepaid on April 9, 2013 to shareholders on the register as at the close ofbusiness on March 8, 2013.Together with the first interim payment of 2.73 US cents per ordinary share(2011: 2.48 US cents per ordinary share), this represents total dividends for2012 of 17.33 US cents per ordinary share (2011: 15.07 US cents per ordinaryshare), an increase of 15% in US Dollar terms.Angus Russell, Chief Executive Officer, commented:"It's been another strong year for Shire with 12% growth in product sales and14% growth in Non GAAP earnings which have driven particularly strong cashgeneration. While delivering strong financial results, we continue to invest inour emerging late stage R&D pipeline.Our ADHD portfolio is performing very well in a growing global market and wesee further growth going forward. The positive opinion received from theEuropean regulators for ELVANSE is a significant milestone and we're nowpreparing for country launches in some of the largest markets in Europe. Allour rare disease treatments continue to grow and we saw particularly strongperformance from FIRAZYR in its first full year in the US market. We advancedour plans for developing our Regenerative Medicine business with theacquisition of VASCUGEL and the approval of DERMAGRAFT in Canada.Our late stage R&D pipeline now holds the prospect of future growth from LDX(the active ingredient in VYVANSE) in major depressive disorder, binge eatingdisorder and negative symptoms of schizophrenia. Our intrathecal programs arealso progressing well as we plan the next clinical trials for Hunter CNS andSanfilippo A and continue to enrol MLD patients into the ongoing Phase 1/2trial. A phase 2b study of SPD602, our iron chelating product, is underway andheadline results are expected later this year.We've completed a number of in-licensing deals and acquisitions in 2012,bringing us new technology platforms in rare diseases, hematology and a rangeof early stage and exciting differentiated treatments.We've put in place our leadership succession plan. Dr. Flemming Ørnskov joinedus at the beginning of January and is familiarising himself with the businessbefore he assumes the role of CEO at the end of April. His considerablepharmaceutical and international experience will benefit Shire going forward.Today we announce that Sylvie Gregoire, President of our HGT business, hasdecided to leave Shire at the end of March, after five years. We're gratefulfor her significant contributions to the growth of Shire through establishingHGT as a leader in rare diseases.Shire is in great shape, with the current business performing well, a promisingpipeline of new growth opportunities, and the strategy in place to deliver anexciting future. As we look forward to the year ahead, we expect our financialresults to show further growth in line with current consensus earningsexpectations for 2013(1)."
FT Article on the dividend Boom
This article which appeared in the Saturday edition of the FT on 27th October talks about investors chasing dividends. It is a good read and vindicates our stance that the only reason to invest in equities at the present time is for Dividends.
Shire Q2 2012 IMS
SHIRE SECOND QUARTER PRODUCT SALES UP 16% ON TRACK TO DELIVER DOUBLE DIGIT FULL YEAR EARNINGS GROWTHAugust 1, 2012 - Shire (LSE: SHP, NASDAQ: SHPG) announces results for the three months to June 30, 2012.
Shire Q1 2012 Results
April 26, 2012 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to March 31,2012.Financial Highlights Q1 2012(1)Product sales $1,107 million +24%Total revenues $1,172 million +21%
Another strong year for Shire
Another strong year for Shire with revenues exceeding $4 billion for the firsttime and Non GAAP EPS up 26% to $5.34.Good 2012 earnings growth expected.February 9, 2012 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialtybiopharmaceutical company, announces results for the year to December 31, 2011.Financial Highlights Full Year 2011(1)Product sales $3,950 million +26%Total revenues $4,263 million +23%Non GAAP operating income $1,357 million +27%US GAAP operating income $1,109 million +40%Non GAAP diluted earnings per ADS $5.34 +26%US GAAP diluted earnings per ADS $4.53 +43%Non GAAP cash generation $1,391 million +3%Non GAAP free cash flow $879 million +11%US GAAP net cash provided by operating activities $1,074 million +12%
Shire 2011 Final results - dividend announced
Another strong year for Shire with revenues exceeding $4 billion for the first time and Non GAAP EPS up 26% to $5.34.Good 2012 earnings growth expected.Financial Highlights Full Year 2011(1)Product sales $3,950 million +26%Total revenues $4,263 million +23%Non GAAP operating income $1,357 million +27%US GAAP operating income $1,109 million +40%Non GAAP diluted earnings per ADS $5.34 +26%
Anthony Hilton in the Evening Standard
Economists and traders in the City have thought and behaved for some months as if the world is coming to an end, but that is not the message delivered by Britain's listed companies. In the past 12 months, they have paid out a record level of dividends. Given that dividends are derived from profits, it suggests this is not a story of a business world on its uppers.
